Molnuvir (Molnupiravir) 200 mg

Molnuvir is manufactured as oral tablets:

• Dosage Form & Packaging: 1 plastic bottle containing 40 tablets, packed in a protective cardboard box.
• Active Ingredient: Molnupiravir — 200 mg per tablet.
• Excipients: Microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, film coating.

Pharmacodynamics: Molnupiravir is metabolized to N4-hydroxycytidine (NHC). In infected cells, NHC is phosphorylated to NHC-TP and incorporated into viral RNA by RNA polymerase. This induces severe mutation accumulation in the viral genome leading to viral inactivation. This mechanism is effective against human RNA viruses and Feline Coronavirus (FCoV/FIPV).

Pharmacokinetics: Rapidly absorbed and converted to active NHC in plasma. High oral bioavailability. Excreted mainly as metabolites via kidneys and feces.

Molnuvir is indicated for:

• 🔹 Human Medical Use: Treatment of mild-to-moderate COVID-19 in adult patients at risk of progression to severe illness (within the first 5 days of symptom onset).
• 🔹 Veterinary Use (Off-label): Treatment of Feline Infectious Peritonitis (FIP) in cats across all clinical forms (wet, dry, ocular, neurological) and for GS-441524 resistant cases.

Administration guidelines for Molnuvir:

• 👤 For Humans: 800 mg (4 tablets of 200 mg) every 12 hours for 5 days. Take orally with water, with or without food.
• 🐾 For Cats (Veterinary Protocol): Dosage is strictly calculated by body weight (typically 12.5–20 mg/kg twice daily for standard FIP, up to 25–30 mg/kg for neurological FIP). Tablets are split accordingly. Standard FIP treatment duration is 84 days (12 weeks) under blood work monitoring.

Molnuvir is contraindicated in:

• ❌ Hypersensitivity to molnupiravir or excipients.
• ❌ Pregnancy and lactation (due to teratogenic and embryofetal toxicity risks).
• ❌ Patients under 18 years of age (human use). In growing kittens, used only under strict veterinary supervision for life-threatening FIP.

Key drug interactions for Molnuvir:

• ⚠️ General Compatibility: Low potential for CYP enzyme interactions, allowing safe co-administration with most standard drugs.
• ⚠️ Veterinary Context: Compatible with supportive veterinary medications (hepatoprotectants, antiemetics) under routine blood checkups.

Strictly contraindicated during pregnancy and breastfeeding. Females of childbearing potential must use effective contraception during treatment and for 4 days after. Males must use contraception during treatment and for 3 months after. Do not use in pregnant or nursing animals.

Potential side effects of Molnuvir:

• 🤢 In Humans: Nausea, diarrhea, dizziness, headache, skin rash.
• 🐾 In Cats: Transient reduced appetite, nausea, mild diarrhea, temporary liver enzyme elevation (ALT/AST).

Symptoms: Exacerbation of gastrointestinal upset, lethargy.

Treatment: No specific antidote. Perform gastric lavage if necessary, give adsorbents, and administer supportive care.

Storage instructions for Molnuvir:

• 🌡️ Temperature: Store in a dry place at temperatures not exceeding 30 °C.
• 💧 Moisture: Keep bottle tightly closed in its original box.
• 👶 Safety: Keep out of reach of children and pets.

Authenticity features of original Molnuvir:

• 🛡️ Branding & Logo: Golden-tree logo of Sacred Leaves Pvt Ltd printed on the box and label. Blue and white theme.
• 🔍 Batch Details: Clearly printed Mfg. Lic. No. (1800-05P), Batch No. (e.g., GT1997), Mfg. Date, and Exp. Date on bottle label and carton.
• 📦 Packaging: White plastic bottle with ribbed safety cap containing 40 tablets.